Profile data is unavailable for this security.
About the company
Onconetix, Inc. is a commercial stage biotechnology company. It is focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. It has Entadfi, a Food and Drug Administration approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology. Entadfi is a once-daily, oral treatment for BPH that combines finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. Proclarix is a next generation protein-based blood test that can be done with the same sample as a patient’s regular PSA test. Proteomedix is seeking to develop diagnostic, prognostic, and predictive tools to enable cancer management at all stages of disease progression.
- Revenue in USD (TTM)758.90k
- Net income in USD-45.68m
- Incorporated2018
- Employees12.00
- LocationOnconetix Inc201 E. Fifth Street, Suite 1900CINCINNATI 45202United StatesUSA
- Phone+1 (513) 620-4101
- Fax+1 (845) 818-3588
- Websitehttps://onconetix.gcs-web.com/
More ▼
Mergers & acquisitions
| Acquired company | ONCO:NAQ since announced | Transaction value |
|---|---|---|
| ProteoMediX Ltd | -30.88% | -- |
Data delayed at least 15 minutes, as of Jul 30 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| cbdMD Inc | 21.58m | -25.65m | 2.03m | 52.00 | -- | 0.5341 | -- | 0.0943 | -19.96 | -19.96 | 9.27 | 1.01 | 0.8949 | 2.09 | 21.27 | 415,039.60 | -89.78 | -38.59 | -118.26 | -41.50 | 62.70 | 63.80 | -100.33 | -87.98 | 0.6107 | -3.01 | 0.4668 | -- | -31.77 | 120.91 | 63.64 | -- | -4.95 | -- |
| 60 Degrees Pharmaceuticals Inc | 378.20k | -1.07m | 2.23m | 2.00 | -- | -- | -- | 5.90 | -0.1563 | -0.1563 | 0.0564 | 0.6121 | 0.0474 | 0.8827 | 1.90 | 126,066.70 | -9.87 | -- | -- | -- | -23.45 | -- | -208.43 | -- | 6.77 | -- | 0.0217 | -- | -50.40 | -- | 35.51 | -- | -- | -- |
| Resonate Blends Inc | 101.41k | -4.72m | 3.00m | 6.00 | -- | -- | -- | 29.54 | -0.0537 | -0.0537 | 0.0012 | -0.0007 | 0.0328 | -- | -- | -- | -152.56 | -680.29 | -- | -- | -34.87 | -78.88 | -4,657.83 | -12,895.26 | -- | -0.7413 | 1.02 | -- | -66.73 | -56.57 | -316.63 | -- | -- | -- |
| China Pharma Holdings Inc | 6.42m | -3.56m | 3.81m | 231.00 | -- | 0.4289 | -- | 0.5932 | -0.8352 | -0.8352 | 1.03 | 0.5596 | 0.3828 | 1.93 | 14.14 | 27,795.89 | -21.22 | -29.66 | -44.77 | -55.25 | -11.67 | 6.47 | -55.42 | -73.09 | 0.2523 | -11.34 | 0.261 | -- | -13.48 | -10.68 | 22.50 | -- | -25.78 | -- |
| Hoth Therapeutics Inc | 0.00 | -7.70m | 3.81m | 2.00 | -- | 0.4386 | -- | -- | -2.02 | -2.02 | 0.00 | 1.78 | 0.00 | -- | -- | 0.00 | -70.17 | -157.07 | -77.15 | -177.32 | -- | -- | -- | -- | -- | -50.67 | 0.00 | -- | -- | -- | 31.01 | -- | -- | -- |
| CYANOTECH CORP | 23.07m | -5.27m | 3.89m | 77.00 | -- | 0.3293 | -- | 0.1687 | -0.7996 | -0.7996 | 3.53 | 1.70 | 0.8414 | 1.90 | 13.44 | 299,623.40 | -19.21 | -3.46 | -27.59 | -4.46 | 25.76 | 34.54 | -22.83 | -3.58 | 0.3832 | -6.87 | 0.3595 | -- | -0.4616 | -5.24 | -53.11 | -- | -6.42 | -- |
| Onconetix Inc | 758.90k | -45.68m | 3.95m | 12.00 | -- | -- | -- | 5.21 | -2.41 | -2.41 | 0.0407 | 1.91 | 0.0156 | -- | 4.70 | 63,241.67 | -93.67 | -- | -137.89 | -- | -123.62 | -- | -6,019.45 | -- | 0.2752 | -17.12 | 0.2352 | -- | -- | -- | -176.78 | -- | -- | -- |
| Hanyuan Biotech International Inc | 10.65m | 3.14m | 4.24m | -- | 0.0236 | 0.0051 | 1.16 | 0.3981 | 0.2246 | 0.2246 | 0.7611 | 1.03 | -- | -- | -- | -- | -- | -- | -- | -- | 68.54 | -- | 29.51 | -- | 13.36 | 25.66 | 0.00 | -- | 50.51 | -- | 106.71 | -- | -- | -- |
| Evoke Pharma Inc | 6.11m | -7.13m | 4.30m | 4.00 | -- | 1.23 | -- | 0.704 | -1.83 | -1.83 | 1.28 | 0.4068 | 0.5429 | 0.5113 | 5.71 | 1,526,428.00 | -63.39 | -100.48 | -76.67 | -151.10 | 96.01 | -- | -116.76 | -480.52 | 5.35 | -19.25 | 0.5884 | -- | 106.51 | -- | 5.25 | -- | -- | -- |
| Sonnet Biotherapeutics Holdings Inc | 92.74k | -8.43m | 4.47m | 12.00 | -- | 0.8727 | -- | 48.19 | -5.28 | -5.28 | 0.0315 | 0.9813 | 0.0097 | -- | 0.2248 | 7,728.33 | -87.68 | -- | -194.11 | -- | -- | -- | -9,086.22 | -- | -- | -138.21 | 0.00 | -- | -57.76 | -- | 36.64 | -- | -- | -- |
| Processa Pharmaceuticals Inc | 0.00 | -9.83m | 4.86m | 13.00 | -- | 0.5466 | -- | -- | -6.29 | -6.29 | 0.00 | 3.11 | 0.00 | -- | -- | 0.00 | -87.82 | -84.35 | -102.32 | -90.03 | -- | -- | -- | -- | -- | -- | 0.0012 | -- | -- | -- | 59.45 | -- | -34.05 | -- |
| Titan Pharmaceuticals Inc | 87.00k | -4.95m | 5.22m | 4.00 | -- | 0.8569 | -- | 59.94 | -6.41 | -6.41 | 0.1119 | 6.66 | 0.0197 | -- | 1.23 | 21,750.00 | -112.41 | -96.80 | -170.59 | -156.65 | -- | -- | -5,694.25 | -406.26 | -- | -415.19 | 0.00 | -- | -66.97 | -51.16 | 45.43 | -- | -65.61 | -- |
| Stemtech Corp | 5.17m | -4.61m | 5.79m | 45.00 | -- | -- | -- | 1.12 | -0.0482 | -0.0482 | 0.0543 | -0.0319 | 1.27 | 13.23 | 80.02 | -- | -113.00 | -- | -- | -- | 78.68 | -- | -89.26 | -- | 0.0563 | -4.06 | -- | -- | 7.94 | -- | 36.45 | -- | -- | -- |
| Sonoma Pharmaceuticals Inc | 12.74m | -4.84m | 5.82m | 172.00 | -- | 0.7782 | -- | 0.4566 | -0.7237 | -0.7237 | 1.40 | 0.3932 | 0.8224 | 2.87 | 4.66 | 74,040.70 | -31.22 | -29.36 | -41.09 | -40.65 | 37.26 | 38.00 | -37.97 | -30.93 | 2.64 | -- | 0.05 | -- | -4.05 | -7.66 | 6.13 | -- | -29.84 | -- |
Data as of Jul 30 2024. Currency figures normalised to Onconetix Inc's reporting currency: US Dollar USD
10.52%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| American Money Management Corp.as of 31 Mar 2024 | 1.44m | 6.45% |
| Cetera Investment Advisers LLCas of 31 Mar 2024 | 320.00k | 1.43% |
| Bank of America, NA (Private Banking)as of 31 Mar 2024 | 125.00k | 0.56% |
| Two Sigma Securities LLCas of 31 Mar 2024 | 113.43k | 0.51% |
| Fifth Third Bank, NA (Investment Management)as of 30 Jun 2024 | 96.20k | 0.43% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 73.51k | 0.33% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 53.56k | 0.24% |
| Geode Capital Management LLCas of 31 Mar 2024 | 53.11k | 0.24% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 38.29k | 0.17% |
| Bahl & Gaynor, Inc.as of 31 Mar 2024 | 34.71k | 0.16% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
